The (B) case shows that Sharer decided that Amgen should be the emerging biosimilars business. Nonetheless, he took the better part of a year to syndicate the decision across the senior team while in parallel investing in some time-critical process development. The (B) case later on emphasizes on how the novel company should be implemented, particularly when it comes to integration versus isolation of a new business unit, selection of unit leader, and whether Amgen should associate with a third party to gain access to skills or resources.
PUBLICATION DATE: January 15, 2014 PRODUCT #: 714426-HCB-ENG
This is just an excerpt. This case is about STRATEGY & EXECUTION
Related Case Solutions & Analyses:
Masdar City
The Grommet
Atlantic Corp.
Valuing Rajat Bhatia’s Business Plan
The UCLA Medical Center: Kidney Transplantation
China’s Banks 2010
Kulicke and Soffa Industries, Inc.: Designing a Supply Chain Network
Cytyc: Transforming Cervical Cancer Testing
Strategies for Building Effective Virtual Teams: Trust is Key
Catalytic Governance
